Eli Lilly launched 'TuneLab,' an AI platform granting selected biotech companies access to pre-trained drug discovery models developed from Lilly’s extensive R&D data. In exchange for access, collaborators contribute proprietary data to refine Lilly's models via federated learning, preserving confidentiality. This platform aims to democratize AI capabilities for smaller biotechs, accelerating drug development and fostering collaborative innovation in pharmaceutical research.